Positive Developments and Financial Stability Underpin Buy Rating for Neurogene’s ‘401 Program

TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating on November 13.

Ritu Baral’s rating is based on several positive developments surrounding Neurogene’s ‘401 program. The recent Phase 1/2 data for ‘401 demonstrated consistent and durable improvements across multiple domains, suggesting that ‘401 could be a leading treatment option. A significant majority of patients met the responder criteria for the EMBOLDEN trial, surpassing the expected success rate, which is a promising indicator for the upcoming Phase 3 results. Additionally, the ‘401 treatment was found to be safe and well-tolerated, with no severe adverse events reported.
Financially, Neurogene appears to be in a strong position, with a cash runway expected to last until the first quarter of 2028. This financial stability supports continued development and potential commercialization of ‘401. The combination of promising clinical data and a solid financial foundation underpins Ritu Baral’s Buy rating for Neurogene’s stock.

According to TipRanks, Baral is a top 100 analyst with an average return of 32.3% and a 57.03% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Palvella Therapeutics, and Avidity Biosciences.